About
NAOR is a platform for rapid RNA diagnosis of COVID-19 and other pathogens. The company uses a one-step nucleic acid amplification method to multiply specific sequences of RNA, resulting in extremely high sensitivity and specificity. The technology enables high-volume lab-grade results in field settings such as airports, schools, and workplaces. The tests can also be conducted at home.
Originally developed at the Technion, the technology combines biochemistry, electronics, and artificial intelligence. The original clinical study (with results from Rambam Medical Center) was one of the first to use rapid RNA testing of the virus. The company has since gathered significant data from around the world and further developed the technology. Its platform is now available in select markets worldwide.
NAOR is developed by Rapid Diagnostic System Ltd.
Funding history · 2 rounds · — total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is NAOR's primary product or service?
- NAOR provides a platform for rapid RNA diagnosis of COVID-19 and other pathogens, utilizing a one-step nucleic acid amplification method for high sensitivity and specificity.
- When was NAOR founded?
- NAOR was founded in July 2020.
- What is the current operational status of NAOR?
- NAOR is currently inactive, having ceased operations in March 2024.
- Where is NAOR's headquarters located?
- NAOR's headquarters is located in Haifa, Israel.
- How many employees did NAOR have?
- NAOR had 7 employees.
- What is the origin of NAOR's core technology?
- NAOR's technology was originally developed at the Technion, combining biochemistry, electronics, and artificial intelligence.
- In which markets is NAOR's platform available?
- NAOR's platform is available in select markets worldwide, including various regions in Asia, Europe, the Americas, Africa, and Oceania.
- What was the focus of NAOR's initial clinical study?
- NAOR's original clinical study, with results from Rambam Medical Center, focused on rapid RNA testing of the virus.